Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations-Reference-Cited by-同舟云学术

Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations

Published:2013-09 Issue:3 Volume:81 Page:435-439
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ichihara Eiki,Hotta Katsuyuki,Takigawa Nagio,Kudo Kenichiro,Kato Yuka,Honda Yoshihiro,Hayakawa Hiromi,Minami Daisuke,Sato Akiko,Tabata Masahiro,Tanimoto Mitsune,Kiura Katsuyuki

Funder

Okayama Institute of Health Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

2. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer;Hotta;J Thorac Oncol,2007

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib;Scientific Reports;2022-04-29

2. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update;Journal of Clinical Oncology;2021-06-20

3. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer;European Journal of Clinical Pharmacology;2020-10-07

4. Expected and paradoxical effects of obesity on cancer treatment response;Reviews in Endocrine and Metabolic Disorders;2020-10-06

5. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib;Investigational New Drugs;2020-05-20